Enhancing the Growth of Natural Eyelashes: The Mechanism of Bimatoprost-Induced Eyelash Growth
Abstract
BACKGROUND: Many women desire prominent eyelashes. In December 2008, bimatoprost ophthalmic solution 0.03% was approved for the treatment of hypotrichosis of the eyelashes in the United States. OBJECTIVE: To review eyelash physiology and the proposed mechanisms by which the topical pros-tamide product bimatoprost enhances eyelash growth. METHODS AND MATERIALS: Clinical and preclinical studies pertaining to the efficacy, safety, and mechanisms of action of bimatoprost are presented. RESULTS: Treatment with bimatoprost increases the percentage of eyelash follicles in anagen at any one time. This probably accounts for its ability to lengthen lashes. Bimatoprost-induced stimulation of melanogenesis appears to result in darker lashes and, at the same time, appears to increase the size of the dermal papilla and hair bulb, affecting lash thickness and fullness. Such effects, largely demonstrated in animal studies, are consistent with the results of a recent Food and Drug Administration phase III clinical trial. The favorable safety profile of bimatoprost in human subjects is probably secondary to the limited exposure of ocular tissues resulting from topical application at the base of the upper lashes. CONCLUSION: By influencing the eyelash hair cycle and follicles, bimatoprost ophthalmic solution 0.03% is a safe and effective means of enhancing eyelash growth. Dr. Cohen has served as a consultant and clinical trial participant for Allergan, Inc.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The efficacy of bimatoprost 0.03% for the treatment of eyelash hypotrichosis was proven by many randomized controlled trials and was approved by the FDA in 2008.
“The efficacy of bimatoprost 0.03% for the treatment of eyelash hypotrichosis was proven by many randomized, controlled trials and was approved by the FDA in 2008 [18].”
Cites
Brandt, J. D., VanDenburgh, A. M., Chen, K., & Whitcup, S. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00584-x · Cited by 152 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zaky, M. S., Hashem, O. A., Mahfouz, S. M., & Elsaie, M. L. (2023) · Archives of Dermatological Research · doi:10.1007/s00403-023-02679-2 · Cited by 6 · see citing works
- Authors
- COHEN, J. L.
- Corresponding author
- COHEN, JOEL L.
- ORCID
- COHEN, JOEL L.
- Venue
- Dermatologic Surgery
- Published
- 2010-09
- Volume
- 36
- Issue
- 9
- Pages
- 1361-1371
- ISSN
- 1076-0512 (ISSN-L)
- OpenAlex
- W1992417737
- Cited by
- 85
- References
- 1
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 9 · 2017: 6 · 2016: 6 · 2015: 11 · 2014: 3 · 2013: 10 · 2012: 3
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dermatologic Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Urology › Hair Growth and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ocular Surface and Contact Lens
- Keywords
- bimatoprost, eyelash growth, anagen phase, melanogenesis, dermal papilla, hair bulb, drug safety, prostamide
- MeSH terms
- Bimatoprost, Amides, Cloprostenol, Eyelashes, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review